105 related articles for article (PubMed ID: 8514100)
1. [The value of etoposide (VP-16) in the therapy of refractory ovarian cancer].
Marth C; Pointner E; Zeimet AG; Abfalter E; Koza A; Windbichler G; Hetzel H; Dapunt O
Geburtshilfe Frauenheilkd; 1993 May; 53(5):303-7. PubMed ID: 8514100
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
[TBL] [Abstract][Full Text] [Related]
4. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
6. Therapy of advanced ovarian juvenile granulosa cell tumors.
Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
[TBL] [Abstract][Full Text] [Related]
9. [A case of poorly differentiated ovarian serous adenocarcinoma responding favorably to etoposide and cisplatin].
Sato Y; Nishida M; Inoue K; Arai Y; Sasaki J; Kubo T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1847-9. PubMed ID: 8937497
[TBL] [Abstract][Full Text] [Related]
10. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
Markman M; Blessing JA; Major F; Manetta A
Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
[TBL] [Abstract][Full Text] [Related]
11. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy.
Moosavi AS; Gilani MM; Tehranian A; Esfahani JK
J Obstet Gynaecol; 2004 Apr; 24(3):292-3. PubMed ID: 15203631
[TBL] [Abstract][Full Text] [Related]
12. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy].
Ivanov S; Ivanov S; Khadzhiolov N
Akush Ginekol (Sofiia); 2004; 43(6):17-9. PubMed ID: 15669647
[TBL] [Abstract][Full Text] [Related]
14. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
15. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
[TBL] [Abstract][Full Text] [Related]
16. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
De Lena M; Lorusso V; Romito S
Cancer Treat Rep; 1986 Jul; 70(7):893-5. PubMed ID: 3719581
[TBL] [Abstract][Full Text] [Related]
18. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
19. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
